Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,229 recruiting studies in this area right now.
By phase
- Not applicable3,142
- Phase 21,065
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4237
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)65
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona141
- New York123
- Massachusetts119
- Texas117
- Illinois82
- Colorado77
Recruiting studies6,229 total
- NCT03223610RecruitingPhase 1/Phase 2
ViPOR treatment for relapsed or hard-to-treat lymphoma
This Phase 1/2 trial tests a combination of several medicines (venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid) for lymphoma that has come back or did not respond. It aims to shrink tumors safely and improve responses in people with specific types of B-cell lymphoma.
Bethesda, MarylandAges 18–120 - NCT03228732RecruitingEarly Phase 1
Fluoxetine and/or DHEA in people with type 1 diabetes
This early-stage study tests whether the medicines fluoxetine and/or DHEA can improve health in adults with type 1 diabetes. It’s mainly looking for people without major diabetes complications or major medical problems to safely study the effects.
Baltimore, MarylandAges 18–50 - NCT03233646Recruiting
Retina scans in memory and nerve disorders
This study uses pictures of the back of your eye (retinal imaging) to look for differences in people with neurodegenerative diseases and compares them with people without these conditions. It may help researchers understand eye changes that could connect to brain or nerve health.
Durham, North CarolinaAges 18 years+ - NCT03245801Recruiting
Juvenile arthritis registry for newly diagnosed children
This study collects information about children with juvenile idiopathic arthritis (JIA) soon after diagnosis. The information helps researchers understand how the condition and treatments change over time, and it may guide future care.
Calgary, AlbertaAges Up to 18 years - NCT03276923Recruiting
Pregnancy registry for women with autoimmune disease
This study is a pregnancy and health registry for women with autoimmune (immune system) conditions who are trying to become pregnant or are already pregnant. It helps researchers better understand pregnancy outcomes and health needs in autoimmune disease.
Durham, North CarolinaAges Any age - NCT03266640RecruitingPhase 2
CMV cell therapy for difficult-to-treat viral infection
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT03266627RecruitingPhase 2
Adenovirus T-cell therapy for hard-to-treat virus after transplants
This trial tests a special immune-cell treatment made to fight adenovirus in people whose adenovirus infection keeps coming back or won’t improve after transplant. It may help control infection when standard antiviral medicines are not working or can’t be tolerated.
Los Angeles, CaliforniaAges 1 month–79 years - NCT03266653RecruitingPhase 2
T-cell therapy for stubborn Epstein-Barr virus after transplants
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT03280394Recruiting
Liquid blood test for mature B-cell tumors
This study looks at how a “liquid biopsy,” a test done on blood, may help in people with mature B-cell tumors. It mainly checks whether you can take part and complete the planned study procedures.
Bellinzona, Canton TicinoAges 18 years+ - NCT03297606RecruitingPhase 2
Match your tumor test to a targeted cancer drug
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
Edmonton, AlbertaAges 18 years+ - NCT03300830Recruiting
Testing tumors linked to viruses, HIV, and immune disorders
This study collects and analyzes tumor tissue to learn what drives certain cancers and growths linked to viruses, HIV, and immune system problems. Results may help researchers understand disease causes and point to better future treatments.
Bethesda, MarylandAges 18 years+ - NCT03297775Recruiting
Studying rheumatoid arthritis treatment risks for lung scarring
This trial is for people with rheumatoid arthritis (RA) who are at risk for developing interstitial lung disease, which is scarring in the lungs. It aims to better understand why this happens and how to help prevent or manage it.
Aurora, ColoradoAges 45–90 - NCT03308474Recruiting
Myeloma patient registry study for treatment experiences
This trial enrolls people with multiple myeloma who are starting (or have recently started) standard drug treatment, so researchers can collect real-world information about patients’ experiences and outcomes. It may help by improving future care planning and study designs, while adding an extra set of questionnaires to your routine.
Multiple SitesAges 18 years+ - NCT03311503RecruitingPhase 1/Phase 2
Gene therapy for X-linked SCID in young children
This trial tests a gene therapy using a lentivirus to give missing immune system instructions in children with X-linked SCID (SCID-X1). It also uses a low dose of targeted chemotherapy (busulfan) to help the new genes work, and it requires long-term follow-up for safety.
Los Angeles, CaliforniaAges birth–5 years - NCT03313271Recruiting
Lymphoma patient registry for people with lymphoma
This is a registry study that collects health information from adults diagnosed with Hodgkin or non-Hodgkin lymphoma. It may help researchers learn about lymphoma care and outcomes by understanding real-world patient experiences.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03326921RecruitingPhase 1
T cell treatment for leukemia after a bone marrow transplant
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
Seattle, WashingtonAges Up to 80 years - NCT03316261Recruiting
Testing newborns for type 1 diabetes risk
This study looks at infants to find how likely they are to develop type 1 diabetes later in life. If you have a newborn who is very young, you may be able to take part by allowing the study team to test them as part of early risk screening.
MunichAges 1 day–1 month - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Phoenix, ArizonaAges 18 years+ - NCT03361215Recruiting
Tracking skin disease patterns and anti-inflammatory response
This study looks at how atopic dermatitis (eczema), psoriasis, or other autoimmune skin diseases change over time and how the body responds to anti-inflammatory signals. Your information and—if eligible—samples help researchers find patterns that could guide better treatments.
KielAges birth–100 years - NCT03394365RecruitingPhase 3
Tabelecleucel for EBV-related lymphoma after transplant treatment failure
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Duarte, CaliforniaAges Any age - NCT03398161RecruitingPhase 2
Very low-dose skin radiation for mycosis fungoides spots
This trial tests whether ultra low-dose radiation can control specific skin lesions from mycosis fungoides (a type of lymphoma that affects the skin). It may help shrink or control targeted spots while using a lower radiation amount.
Houston, TexasAges 18 years+ - NCT03399175Recruiting
Early immune-suppressing treatment for VKH eye disease
This trial studies giving immune-suppressing treatment early in Vogt-Koyanagi-Harada (VKH) disease to see if it improves outcomes. It may help people reduce ongoing eye inflammation if they qualify and can be followed for a longer time.
São Paulo, São PauloAges 10–70 - NCT03404336Recruiting
Well-being therapy for chronic migraine in outpatients
This study tests whether a “well-being therapy” program can reduce symptoms of chronic migraine compared with a control therapy. You may qualify if you have long-lasting chronic migraine and can follow the study schedule.
Florence, FlorenceAges 18–65 - NCT03401879Recruiting
Study eye blood-flow changes in multiple sclerosis
This study measures how blood flow in the eye changes in people with relapsing-remitting multiple sclerosis (RRMS) who previously had optic neuritis. The goal is to understand eye/brain blood-flow signals and how they may relate to MS.
Vienna, AustriaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,229 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,721 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.